EUVIMEDEUVIMED entdecken
Crossref

A Modular Endogenous‐Responsive DNA Nanosponge for Cancer‐Selective RNA Demethylase Imaging and Concurrent Photodynamic Therapy

Yun Han, Weijie Tong, Fei Ma iD, Chun-Yang Zhang

Small · 2026

DOI: 10.1002/smll.74992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2026. Verfasst von Yun Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Photochemotherapy, DNA, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Frontier Technologies R&D Program of Jiangsu, National Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA demethylase plays a crucial role in the dynamic regulation of m 6 A modification and has been identified as promising biomarker and therapeutic target. However, real‐time monitoring of its activity in living cells remains challenging due to poor probe stability, and lack of tumor selectivity. Herein, we develop a cancer‐targeting, endogenous‐activated DNA nanosponge (DNS) platform for cancer‐selective FTO imaging. The DNS is constructed via rolling circle amplification and loaded with FTO‐responsive DNAzyme probes (FDz) and photosensitizer zinc phthalocyanine (ZnPc) to form FDz‐ZnPc@DNS. The FDz are initially silenced by m 6 A modification and conjugated to DNS via glutathione (GSH)‐cleavable disulfide linkage. Upon folate receptor‐mediated internalization of FDz‐ZnPc@DNS into cancer cells, intracellular GSH triggers the release of FDz. Subsequent FTO‐mediated demethylation reactivates the DNAzyme, leading to amplified fluorescence recovery for FTO imaging. Concurrently, under 660 nm laser illumination, ZnPc generates cytotoxic singlet oxygen to destroy cancer cells/tissues via photodynamic therapy. Both in vitro and in vivo studies validate the feasibility of this nanoplatform for cancer‐selective imaging and effective treatment. This work presents a robust and versatile nanoplatform that merges targeted delivery and endogenous activation for precise cancer imaging and therapy, with the potential for adaptation to diverse sensing and therapeutic payloads through modular reprogramming.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyDNANeoplasmsHumansAnimalsZinc CompoundsIsoindolesOrganometallic CompoundsIndolesCell Line, TumorDNA, CatalyticPhotosensitizing Agents

Stichwörter der Autor:innen

DNA nanospongeDNAzymeFTOm6Aphotodynamic therapy

Substanzen

DNAZinc CompoundsIsoindolesOrganometallic CompoundsIndolesZn(II)-phthalocyanineDNA, CatalyticPhotosensitizing Agents

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing, China.

ORCID-Profile: Fei Ma

Förderung

  • Frontier Technologies R&D Program of Jiangsu
  • National Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Han, Y., Tong, W., Ma, F., & Zhang, C. Y. (2026). A Modular Endogenous‐Responsive DNA Nanosponge for Cancer‐Selective RNA Demethylase Imaging and Concurrent Photodynamic Therapy. Small. https://doi.org/10.1002/smll.74992

Vancouver

Han Y, Tong W, Ma F, Zhang CY. A Modular Endogenous‐Responsive DNA Nanosponge for Cancer‐Selective RNA Demethylase Imaging and Concurrent Photodynamic Therapy. Small. 2026. doi:10.1002/smll.74992

BibTeX
@article{Han2026,
  author = {Han, Yun and Tong, Weijie and Ma, Fei and Zhang, Chun-Yang},
  title = {A Modular Endogenous‐Responsive DNA Nanosponge for Cancer‐Selective RNA Demethylase Imaging and Concurrent Photodynamic Therapy},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.74992}
}
Kostenlos starten →